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Background: Schistosomiasis, a parasitic disease also known as bilharzia and snail fever, is caused by different
species of flatworms, such as Schistosoma mansoni (S. mansoni). Thioredoxin glutathione reductase (TGR) from S.
mansoni (SmTGR) is a well-characterized drug target for schistosomiasis, yet no anti-SmTGR compounds have
reached clinical trials, suggesting that therapeutic development against schistosomiasis might benefit from
additional scaffolds targeting this enzyme.
Methods: A high-throughput screening (HTS) assay in vitro against SmTGR was developed and applied to a diverse
compound library. SmTGR activity was quantified with ThioGlo®, a reagent that fluoresces upon binding to the free
sulfhydryl groups of the reaction product GSH (reduced glutathione).
Results: We implemented an HTS effort against 59,360 synthetic compounds. In the primary screening, initial hits
(928 or 1.56 %) showing greater than 90 % inhibition on SmTGR activity at a final concentration of 10 μM for
each compound were identified. Further tests were carried out to confirm the effects of these hits and to explore
the concentration-dependent response characteristics. As a result, 74 of them (0.12 %) representing 17 chemical
scaffolds were confirmed and showed a great concentration-dependent inhibitory trend against SmTGR,
including structures previously shown to be lethal to schistosomal growth. Of these, two scaffolds displayed a
limited structure-activity relationship. When tested in cultured larvae, 39 compounds had cidal activity in 48 h,
and five of them killed larvae completely at 3.125 μM. Of these, three compounds also killed adult worms ex vivo
at concentrations between 5 μM and 10 μM.
Conclusion: These confirmed hits may serve as starting points for the development of novel therapeutics to
combat schistosomiasis.
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Schistosome parasites infect an estimated 200 million
people, of which 20 million have significant morbidity,
resulting in more than 200,000 deaths annually. It is
estimated that nearly 800 million people are at risk of
infection [1–3]. At present, schistosomiasis control
strategies rely almost exclusively on chemotherapy;
tens of millions of people are treated with the only
available drug, praziquantel (PZQ) [4, 5]. With the
current levels of drug use, it is inevitable that PZQ-
resistant parasites will evolve. Since no new drugs are
in the clinical pipeline to replace it, it is imperative
to identify new targets and drug candidates for schis-
tosomiasis treatment.
Mechanisms to maintain redox balance have been
shown to be essential for schistosome worm survival.
Previous studies have found significant differences be-
tween the redox network of schistosomes and their
human hosts, with worm defenses being significantly
less robust [6–9]. An important chokepoint in the
redox network is thioredoxin glutathione reductase
(TGR), which replaces three enzyme activities found
in humans: glutathione reductase, thioredoxin reduc-
tase, and glutaredoxin (deglutathionylation) [8, 9].
Using RNAi (RNA interference) and chemical probes,
TGR has been shown to be an essential worm protein
and a druggable target. A screen against the schisto-
some redox pathway of TGR and peroxiredoxin-2
identified oxadiazole-2-oxides as novel TGR inhibitors
with significant in vivo activity against laboratory in-
fections [10–13]. Here we present results from a new
high-throughput screening (HTS) effort against Schis-
tosoma mansoni (S. mansoni) TGR (SmTGR). Several
novel compounds have been discovered with activity
against SmTGR, cultured larval, and adult worms.
These compounds may serve as starting points for
the development of new therapeutic agents to combat
schistosomiasis.Methods
Reagents
Thioredoxin glutathione reductase (EC 1.8.1.B1) from
S. mansoni (SmTGR) was produced at the laboratory
of Dr. Wesley Van Voorhis (University of Washington,
Seattle, WA, USA) by methods described previously [8].
Naphthazarin, oxidized glutathione (GSSG), β-nicotinamide
adenine dinucleotide 2’-phosphate reduced tetrasodium salt
hydrate (NADPH), and ethylenediaminetetraacetic acid
(EDTA) were supplied by Sigma-Aldrich (St. Louis, MO,
USA). Bovine serum albumin (BSA) was the product of
AMRESCO (Solon, OH, USA). ThioGlo® 1 Fluorescent
Thiol Reagent was obtained from Merck (Darmstadt,
Germany).Endpoint SmTGR assay
SmTGR protein (1.58 μg/ml) was loaded into each well
of black 384-well plates (PerkinElmer, Boston, MA,
USA) containing 19 μl of assay buffer I (90 mM Tris-
HCl, 10 mM EDTA, pH 7.5, 100 μM NADPH, and
0.48 mg/ml BSA), followed by an addition of 1 μl posi-
tive control or test compounds. The plates were sealed
and incubated for 50 min at room temperature. Then,
10 μl of assay buffer II (90 mM Tris-HCl, 10 mM EDTA,
pH 7.5, and 100 μM NADPH) supplemented with
150 μM GSSG was added to give a final volume of 30 μl
per well. Following a 1 h incubation, the product was
reacted with 30 μl ThioGlo® 1 reagent for 20–30 min,
and the fluorescence signal was monitored at an excita-
tion wavelength of 380 nm and an emission wavelength
of 515 nm on the EnVision plate reader (PerkinElmer).
Compound library
The compound library comprising 59,360 synthetic com-
pounds was provided by Novo Nordisk A/S (Bagsværd,
Denmark). The structural diversity covers heterocycles,
lactams, sulfonates, sulfonamides, amines, secondary
amides, and natural product-derived compounds. The
compounds were highly purified and the stock, pre-
dissolved in 100 % dimethyl sulfoxide (DMSO) solution,
was applied to the primary screening with an average
final concentration of 10 μM for each compound.
High-throughput screening experiment
An HTS effort was carried out against the compound li-
brary described above. In each of the 384-well plates, 64
wells of the outer four columns were used as high-, mid-,
and low-concentration of naphthazarin controls (final
concentrations: 30 μM, 1.5 μM, and 0.5 μM, respectively)
and negative control (3.3 % DMSO), each with 16 repli-
cates. The test compounds were placed in the center col-
umns 3–22. Both uninhibited (DMSO) and fully inhibited
(30 μM naphthazarin) signals were assessed and the
Z' factor was calculated according to the literature [14].
Taking 30 μM naphthazarin to represent 100 % inhibition,
compounds showing greater than 90 % inhibition were
considered as ‘hits’. All initial hits were rescreened and
further studied for concentration-dependent response
characteristics.
Studies with parasites
Cercariae were shed from infected Biomphalaria glab-
rata snails, obtained from the Biomedical Research
Institute (Rockville, MD, USA), and mechanically trans-
formed to schistosomula as described [15]. Approxi-
mately 300 freshly prepared schistosomula were placed
in each well of a 24-well plate containing 1 ml Basch’s
Complete Medium 169 (with the addition of 10 % fetal
bovine serum) and incubated overnight at 37 °C in 5 %
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added to each well at the indicated concentrations and
the parasites were observed for several days for dead
(dark, granular appearance, and non-motile) or alive
(translucent and motile) as described [16]. Adult para-
sites were obtained from female Swiss Webster mice
seven weeks after infection by perfusion with RPMI
Medium 1640 (Thermo Fisher Scientific, Waltham, MA,
USA) using standard methods [15]. Live worms were
washed thoroughly with Dulbecco’s Modified Eagle’s
Medium (Life Technologies, Carlsbad, CA, USA), and
incubated in 5 ml Basch’s Complete Medium 169 [17] in
6-well tissue culture plates with ten worm pairs per well,
and cultured overnight in 5 % CO2 at 37 °C. The follow-
ing day, media were removed from each well and re-
placed with 5 ml of fresh media. Test compounds were
dissolved in DMSO at 10 mM and added to the wells at
the indicated concentrations. The same volume of
DMSO was added to each well. Negative control worms
were treated with an equal volume of DMSO alone. Each
well was replaced with fresh media and compounds every
48 h. Worm mobility and survival were observed under a
Zeiss Stemi 2000-C stereomicroscope (Carl Zeiss, Jena,
Germany) for 10 sec per worm. This study was approved
by the Institutional Animal Care and Use Committee at
Rush University Medical Center (IACUC number 14–080;
DHHS animal welfare assurance number A3120-01).
Data analysis
Data were analyzed using GraphPad Prism® software
(GraphPad, San Diego, CA, USA). Nonlinear regression
analyses were performed to calculate IC50 values. Values
presented are means ± standard error of the mean (SEM)
of at least three independent experiments. Percentage
inhibition of SmTGR activity by hit compounds was cal-
culated after defining the response to 30 μM naphtha-
zarin as 100 % inhibition.
Results
Assay optimization and validation
Recombinant SmTGR was expressed and purified as
previously described [8]. An earlier assay of the coupled
activities of SmTGR and peroxiredoxin-2 [13] was
adapted to study the activity of SmTGR alone, using the
following principle: SmTGR converts NADPH and
GSSG to NADP+ and reduced glutathione (GSH), and
GSH production can be detected with ThioGlo®, a malei-
mide derivative of the naphthopyranone fluorophore
which fluoresces upon reacting with free thiol groups
such as those present in GSH. We performed the assay
in 384-well plates with a reaction volume of 30 μl before
addition of ThioGlo®. Final concentrations prior to Thio-
Glo® addition were 1 μg/ml SmTGR, 100 μM NADPH,
and 50 μM GSSG in a buffer of 90 mM Tris-HCl,pH 7.5, with 10 mM EDTA and 0.45 mg/ml BSA. After
60 min of room-temperature incubation, the reaction
was stopped with 30 μl of 20 μM ThioGlo 1 (Covalent
Associates, Corvallis, OR, USA). After ten additional mi-
nutes, samples were excited at 380 nM and read for
fluorescence at 515 nM.
High-throughput screening parameters and execution
Under the above optimized assay conditions, we ob-
served good dose responses to naphthazarin with an
IC50 of 1.42 ± 0.08 μM (see Fig. 1a). This value is com-
parable to that documented in the literature (10 μM) [8].
Naphthazarin at 30 μM produced a full inhibition
(100 %; background signal) of SmTGR in this assay (see
Fig. 1b), whereas DMSO alone (served as a negative con-
trol) did not show any inhibition (0 %) on SmTGR activ-
ity (total signal). As a result, the coefficient of variation
(CV) values were 3.40 % for total signal and 13.92 % for
background signal, respectively. The Z' factor calculated
is 0.859 with a signal-to-background ratio (S/B) of 46.76
(see Fig. 1b). These characteristics indicate that the assay
system is of high quality and well suited to HTS [14]. Of
the 59,360 samples initially screened, 928 hits (1.56 %)
showed greater than 90 % inhibition on SmTGR activity
(see Fig. 2). Secondary screening confirmed that 74
(0.12 %) of the above hits displayed consistent inhibitory
effects on SmTGR with IC50 values ranging between
3 nM and 50 μM (see Table 1).
The 74 confirmed hits can be divided into 17 scaffolds
according to their different structure characteristics:
(1) 3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3
(2H)-dione (e.g., WNN0256-E003) and 3a,4,7,7a-tetra-
hydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (e.g., WN
N0724-H007 and WNN0809-E009); (2) 1H-pyrrole-2,5-
dione (e.g., WNN0434-C002, WNN1041-F010, WNN03
28-C003, and WNN1087-E003) and its reductive prod-
uct pyrrolidine-2,5-dione (e.g., WNN0625-C003); (3) 5-
nitro-2-(phenylsulfonyl)pyridine (e.g., WNN0397-C010
and WNN0042-E008); (4) ((hydrazono)methyl)phenol
(e.g., WNN0929-D011 and WNN0929-D007); (5) 5-(5-
nitrothiazol-2-yl)thio)-4H-1,2,4-triazol-3-ol (e.g., WNN
0464-C005 and WNN0464-F002); (6) benzoquinone
(e.g., WNN0474-E006, WNN0366-E010, WNN0544-A
007, and WNN0912-G011); (7) 5-bromo-3,4-dinitrot
hiophen-2-amine (e.g., WNN0197-D004, WNN0429-D
003, and WNN0446-H009) and thiophene derivatives
(e.g., WNN0194-D004 and WNN0373-D002); (8) 3-thio
-4H-1,2,4-triazole (e.g., WNN0464-C004 and WNN06
09-E009) and 2,5-dithio-1,3,4-thiadiazole (e.g., WNN01
92-H003); (9) 2-phenyl-2,3-dihydro-1H-naphtho[1,2-e]
[1,3]oxazine (e.g., WNN0029-D010 and WNN0029-
D009); (10) benzo[d][1,3]oxathiol-2-one (e.g., WNN0113-
H010, WNN0113-H004, and WNN0113-H003) and its
condensation product (e.g., WNN0224-E010); (11) multi-
Fig. 1 Validation of the HTS assay. a Concentration-dependent inhibitory activity of naphthazarin on SmTGR under the optimized assay conditions,
from which the IC50 value was calculated (n = 3, mean ± SEM). b Z' factor determination. Assays were performed under the optimized conditions and
160 replicates of total and background signals were studied. HTS assay parameters, including Z' factor and S/B were examined. Raw fluorescence units
(Y-axis in the left) from each of the controls and % inhibition (Y-axis in the right) are shown. Dashed lines indicate means and mean ± 3 × standard
deviation of the 160 data points
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WNN0009-G004, WNN0341-B004, and WNN0287-H
004); (12) phenylsulfonyl (e.g., WNN0621-C011 and
WNN0367-F009) or pyridinylsulfonyl derivative (e.g.,
WNN0189-G005); (13) 5-membered heterocycles sub-
stituted with nitro or methylsulfonyl group (e.g.,
WNN0809-C005, WNN0009-H010 and WNN0409-G007);
(14) nitro substituted benzo[b]thiophene derivatives
(WNN0197-G002, WNN0009-A002, and WNN0925-Fig. 2 Primary HTS experiment. A collection of 59,360 compounds were sc
average final concentration of 10 μM for each compound. Sixteen positive
plated to calculate % inhibition. Dashed line indicates 90 % inhibition of thB011); (15) benzofuran (e.g., WNN0463-G011) and
2,3-dihydrobenzofuran (e.g., WNN0029-C005 and WNN
0726-A010); (16) benzo[c][1,2,5]oxadiazole (e.g., WNN
0335-G006 and WNN0961-C005); and (17) quinolin-
2(1H)-one (e.g., WNN0374-G010 and WNN0304-A007).
A limited structure-activity relationship (SAR) could
be inferred from some of the scaffolds: for instance, in
scaffold (5) (WNN0464-C005 versus WNN0464-F002),
N-substituent including cycloalkyl and alkyl chain hadreened using the optimized endpoint SmTGR fluorescence assay at an
(30 μM naphthazarin) and negative (DMSO) control reactions were
e initial threshold for hits
Table 1 Structures of the confirmed hits and their inhibition of SmTGR and cidal activities against worms
Compound Structure IC50 (μM)
a Efficacy (%)a Larvab(μM) Adultc(μM)
WNN0724-H007 0.424 ± 0.106 98.57 ± 1.36 50 –e
WNN0809-E009 3.848 ± 0.311 99.60 ± 0.26 n.a.d –
WNN0256-E003 4.476 ± 0.905 98.99 ± 0.45 n.a. –
WNN0434-C002 1.448 ± 0.141 98.48 ± 1.48 25 –
WNN1041-F010 3.181 ± 0.636 97.34 ± 3.30 n.a. –
WNN0328-C003 5.362 ± 0.453 99.41 ± 0.09 n.a. –
WNN0625-C003 2.981 ± 0.438 98.69 ± 1.42 n.a. –
WNN1087-E003 13.21 ± 1.775 95.92 ± 0.12 n.a. –
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Table 1 Structures of the confirmed hits and their inhibition of SmTGR and cidal activities against worms (Continued)
WNN0397-C010 0.862 ± 0.120 95.55 ± 2.02 3.125 n.a.
WNN0042-E008 1.614 ± 0.375 94.31 ± 1.53 n.a. –
WNN0929-D011 0.957 ± 0.232 97.08 ± 1.53 50 –
WNN0929-D007 3.576 ± 0.417 97.86 ± 0.21 n.a. –
WNN0464-C005 1.038 ± 0.198 98.23 ± 2.04 25 –
WNN0464-F002 1.667 ± 0.325 97.51 ± 0.75 12.5 –
WNN0474-E006 2.410 ± 0.438 97.22 ± 0.81 n.a. –
WNN0366-E010 2.605 ± 0.544 73.26 ± 1.61 6.25 –
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Table 1 Structures of the confirmed hits and their inhibition of SmTGR and cidal activities against worms (Continued)
WNN0544-A007 5.595 ± 0.431 98.62 ± 1.50 n.a. –
WNN0912-G011 6.633 ± 1.209 96.87 ± 2.64 n.a. –
WNN0197-D004 3.152 ± 0.509 96.75 ± 0.68 3.125 5
WNN0429-D003 7.243 ± 0.530 98.57 ± 0.63 50 –
WNN0446-H009 6.290 ± 0.177 85.95 ± 2.33 50 –
WNN0194-D004 3.238 ± 0.481 98.65 ± 1.37 50 –
WNN0373-D002 3.352 ± 0.481 82.32 ± 1.51 6.25 –
WNN0464-C004 3.029 ± 0.410 95.73 ± 0.86 6.25 –
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Table 1 Structures of the confirmed hits and their inhibition of SmTGR and cidal activities against worms (Continued)
WNN0609-E009 7.662 ± 0.870 82.93 ± 1.20 3.125 n.a.
WNN0192-H003 4.900 ± 0.955 94.49 ± 1.31 n.a. –
WNN0029-D010 7.919 ± 0.488 97.19 ± 0.74 n.a. –
WNN0029-D009 11.89 ± 0.474 92.95 ± 0.40 n.a. –
WNN0224-E010 11.62 ± 0.346 99.21 ± 0.21 50 –
WNN0113-H010 12.78 ± 0.841 92.49 ± 1.05 n.a. –
WNN0113-H004 9.286 ± 0.622 77.86 ± 2.78 n.a. –
WNN0113-H003 13.08 ± 0.643 74.21 ± 1.41 n.a. –
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Table 1 Structures of the confirmed hits and their inhibition of SmTGR and cidal activities against worms (Continued)
WNN0009-G004 2.595 ± 0.233 98.03 ± 1.12 12.5 –
WNN0341-B004 6.076 ± 0.849 98.97 ± 0.87 n.a. –
WNN0287-H004 3.257 ± 0.792 91.03 ± 0.45 25 –
WNN0189-G005 15.73 ± 1.351 77.53 ± 0.99 n.a. –
WNN0621-C011 8.643 ± 0.912 78.09 ± 2.19 n.a. –
WNN0367-F009 0.612 ± 0.057 98.35 ± 1.32 25 –
WNN0809-C005 17.63 ± 0.863 99.20 ± 0.62 6.25 –
WNN0009-H010 28.61 ± 1.131 96.77 ± 0.49 50 –
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Table 1 Structures of the confirmed hits and their inhibition of SmTGR and cidal activities against worms (Continued)
WNN0409-G007 3.548 ± 0.064 98.56 ± 1.56 n.a. –
WNN0197-G002 5.438 ± 0.552 98.09 ± 1.56 3.125 10
WNN0009-A002 14.47 ± 0.990 82.47 ± 1.70 50 –
WNN0925-B011 1.352 ± 0.123 94.87 ± 0.19 n.a. –
WNN0029-C005 0.003 ± 0.001 97.40 ± 1.50 12.5 –
WNN0726-A010 2.614 ± 0.262 98.70 ± 1.63 50 –
WNN0463-G011 7.171 ± 0.226 95.20 ± 2.54 n.a. –
WNN0335-G006 13.05 ± 0.028 94.88 ± 1.48 12.5 –
WNN0961-C005 2.643 ± 0.276 95.77 ± 1.08 n.a. –
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Table 1 Structures of the confirmed hits and their inhibition of SmTGR and cidal activities against worms (Continued)
WNN0374-G010 4.995 ± 0.290 72.99 ± 3.01 50 –
WNN0304-A007 2.886 ± 0.976 97.56 ± 2.98 50 –
WNN0826-B004 2.214 ± 0.799 93.88 ± 0.17 25 –
WNN0893-H007 5.019 ± 0.212 95.89 ± 1.26 n.a. –
WNN0196-F005 6.719 ± 0.233 73.87 ± 0.93 50 –
WNN0493-F008 6.305 ± 0.523 78.85 ± 2.35 3.125 10
WNN0395-A008 7.871 ± 0.728 98.51 ± 1.39 n.a. –
WNN1018-E008 11.98 ± 0.898 95.62 ± 2.29 n.a. –
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Table 1 Structures of the confirmed hits and their inhibition of SmTGR and cidal activities against worms (Continued)
WNN1177-H006 0.831 ± 0.113 98.02 ± 1.44 n.a. –
WNN0263-A002 16.14 ± 0.884 98.88 ± 0.79 6.25 –
WNN0035-G011 18.23 ± 1.591 96.60 ± 0.67 12.5 –
WNN1177-F009 1.576 ± 0.304 97.00 ± 1.41 n.a. –
WNN0572-G004 2.119 ± 0.502 98.46 ± 1.61 50 –
WNN0493-H007 3.057 ± 0.495 98.71 ± 0.83 n.a. –
WNN0826-A003 2.862 ± 0.163 97.36 ± 1.75 50 –
WNN0307-H007 7.348 ± 0.219 98.44 ± 0.80 50 –
WNN0045-G003 9.057 ± 1.117 98.78 ± 0.76 12.5 –
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Table 1 Structures of the confirmed hits and their inhibition of SmTGR and cidal activities against worms (Continued)
WNN0004-A011 0.004 ± 0.001 95.89 ± 4.91 50 –
WNN0058-C010 0.562 ± 0.071 77.47 ± 1.08 50 –
WNN0433-C010 1.938 ± 0.431 85.21 ± 2.02 n.a. –
WNN0151-C005 3.286 ± 0.240 97.06 ± 1.17 n.a. –
WNN0646-C002 14.78 ± 1.619 90.0 ± 1.379 12.5 –
WNN0040-H011 46.90 ± 5.544 96.74 ± 0.72 n.a. –
WNN0341-C002 4.395 ± 0.403 90.48 ± 1.06 n.a. –
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Table 1 Structures of the confirmed hits and their inhibition of SmTGR and cidal activities against worms (Continued)
WNN0826-A007 0.205 ± 0.148 98.36 ± 1.29 n.a. –
aThe values shown are means ± SEM of at least three independent experiments. bCompounds were tested against larval worms at 50, 25, 12.5, 6.25, and 3.125 μM.
The lowest concentration resulting in 100 % larval death at 48 hours is indicated. cCompounds were tested against adult worms at 10 and 5 μM. The lowest
concentration resulting in 100 % worm death on day seven is indicated
dn.a.: no activity; e-: not tested
Bold phase indicates compounds in the same scaffold
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F002 exhibiting better worm-killing activity ex vivo; in
scaffold (7) (WNN0197-D004 versus WNN0429-
D003), substituents including ethyl and benzyl on the
amino group also showed no obvious difference for
TGR inhibition, however, WNN0197-D004 was active
ex vivo. Among all these hits, furoxan (WNN0809-
C005) and benzofuroxan (WNN0335-G006) were
well-studied structural motifs as nitric oxide (NO) do-
nating compounds capable of controlling schistosom-
iasis [11, 18]. The mechanism involved in this action
includes nucleophilic attack by the sulfhydryl moiety of
a cysteine residue or by selenocysteine at either three
or four-position of the oxadiazole, and subsequent re-
arrangement to release the nitroxyl anion (NO−).
Further SAR analysis showed that the presence of elec-
tron withdrawing groups at three-position generally
increased its capacity. Fruttero and co-workers
reported that furoxans could inhibit the activity of
P-glycoprotein, MRP1, and MRP3 (multidrug resist-
ance-associated proteins) transporters in different types
of cells, which were considered as potentially attractive
targets for the development of new therapeutic agents
against schistosomal infection [19].Ex vivo activity against parasites
The 74 confirmed hits were screened against cultured,
larval parasites at 50 μM (see Table 1). We found that
53 % (39/74) of the compounds had cidal activity at
48 h. They were subsequently tested against larva at 25,
12.5, 6.25, and 3.125 μM (see Table 1). Of them, five
were found to kill 100 % of larva at 48 h at 3.125 μM
(see Table 1). These five hits were further tested ex vivo
against adult worms, with two killing adult worms at
10 μM (WNN0197-G002 and WNN0493-F008) and one
killing adult worms at 5 μM (WNN0197-D004; see
Table 1).Discussion
To date, PZQ is the only drug used to treat the disease,
and with its increased use the probability of developing
resistance has grown significantly. Therefore, it is im-
portant to identify new drugs to replace PZQ or, prefera-
bly, to be used in combination with PZQ to prevent
resistance from developing. It is known that S. mansoni
survives in humans partly because of the existence of a
set of antioxidant enzymes that continuously degrade
reactive oxygen species produced by the host. A key
element of this defense system is TGR, a parasite-
specific enzyme combining the functions of three human
counterparts: glutathione reductase, thioredoxin reduc-
tase, and glutaredoxin. Although a recent study reported
that RNAi helped validate novel and putative drug tar-
gets for schistosomiasis [20], TGR remains an attractive
one and has been subject to HTS studies using different
assay systems [13, 21]. In this study, we used recombin-
ant SmTGR and adapted a novel coupled assay to meas-
ure TGR activity alone, which in turn was optimized for
HTS [14]. This validation process was successful as
demonstrated by a comparable IC50 value measured for
the positive control, naphthazarin (see Fig. 1a), and
other high quality assay parameters such as CV, Z' factor,
and S/B (see Fig. 1b).
In the primary screening, a total of 59,360 synthetic
compounds were screened and 928 initial hits were identi-
fied (1.56 %) using 90 % inhibition on SmTGR activity as a
cut-off point. The initial hits were further characterized in
dose–response experiments, of which 74 compounds dis-
played consistent inhibitory properties. When assessed for
ex vivo activity against parasites, 39 hits showed cidal ef-
fects in 48 h, and five of them displayed 100 % killing at
3.125 μM; of these, two killed adult worms at 10 μM
(WNN0197-G002 and WNN0493-F008) and one at 5 μM
(WNN0197-D004), respectively. The bioactivity data
shown in Table 1 indicate that there is no real trend
or relationship between TGR inhibition and worm-
Li et al. Infectious Diseases of Poverty  (2015) 4:40 Page 15 of 16killing activity. This phenomenon is not surprising as
drug uptake by worms is usually the limiting factor in
compound activity. In previous studies, most worm-
killing activity was seen only at high nanomolar or low
micromolar concentrations, e.g., 0.3–1 μM for PZQ
[22]. This may be due to slow metabolism of worms
cultured ex vivo, low compound uptake by worms, or
many other factors. Three confirmed hits (WNN0197-
G002, WNN0493-F008, and WNN0197-D004) were
more active against worms than against TGR suggest-
ing they hit other targets. TGR inhibitors are fre-
quently electrophiles [10] and some of the more
potent TGR inhibitors identified in this study have
strong electrophilic centers (e.g., nitro, sulfonyl,
methylsulfonyl, etc.), and might react with thiols and/
or other components in the media thereby reducing
their ability to kill worms.
Conclusion
Clearly, use of TGR as a molecular target to identify
chemical compounds with inhibitory property is a viable
approach in the development of therapeutic agents
against schistosomiasis. The HTS system optimized in
this study is both robust and easy to perform; it provides
an alternative to other screening assays such as NADPH
fluorescence [13] and DTNB (5,5’ dithiobis(2-nitroben-
zoic acid) reduction [21] focusing on this enzyme.
Identification of hits with structures similar to those pre-
viously shown to kill the parasite further supports the
assay validity. Of the 74 hits discovered, the large variety
of scaffolds offers adequate chemical space for lead gen-
eration and other follow-up investigations, though some
of them may represent false positives that require sec-
ondary verification of their functionality. In this regard,
the present study will certainly attract attention from
scientists who are engaged in schistosomiasis research.
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